A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
Status:
Completed
Trial end date:
2015-09-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and dose response of intranasal
esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with
placebo in improving depressive symptoms in participants with treatment-resistant depression
(TRD).